for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Agios Pharmaceuticals Inc

AGIO.O

Latest Trade

31.03USD

Change

-0.11(-0.35%)

Volume

583,887

Today's Range

30.77

 - 

32.30

52 Week Range

29.21

 - 

62.16

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
31.14
Open
31.18
Volume
583,887
3M AVG Volume
11.77
Today's High
32.30
Today's Low
30.77
52 Week High
62.16
52 Week Low
29.21
Shares Out (MIL)
54.31
Market Cap (MIL)
1,691.17
Forward P/E
1.21
Dividend (Yield %)
--

Next Event

Q4 2021 Agios Pharmaceuticals Inc Earnings Release

Latest Developments

More

CENTOGENE Expands Partnership With Agios To Generate Novel Insights Into Rare Blood Diseases

Agios Announces FDA Acceptance And Priority Review Of New Drug Application For Mitapivat For Treatment Of Adults With Pyruvate Kinase Deficiency

Agios Submits New Drug Application To FDA For Mitapivat For Treatment Of Adults With Pyruvate Kinase Deficiency

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.

Industry

Business Services

Contact Info

88 Sidney St

CAMBRIDGE, MA

02139-4137

United States

+1.617.6498600

http://www.agios.com/

Executive Leadership

David P. Schenkein

Chairman of the Board

Jacqualyn A. Fouse

Chief Executive Officer, Director

Jonathan Prim Biller

Chief Financial Officer, Head of Legal and Corporate Affairs

T. J. Washburn

Principal Accounting Officer

Bruce Car

Chief Scientific Officer

Key Stats

2.36 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.2K

2021(E)

0.0K
EPS (USD)

2018

-6.030

2019

-6.860

2020

-4.740

2021(E)

25.790
Price To Earnings (TTM)
--
Price To Sales (TTM)
38.40
Price To Book (MRQ)
1.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.03
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-30.62
Return on Equity (TTM)
-29.03

Latest News

Latest News

Agios to sell cancer business to Servier for potentially $2 billion

Agios Pharmaceuticals Inc said on Monday it had agreed to sell its cancer business to privately held company Servier for potentially $2 billion, as the drugmaker looks to raise money to focus on its genetic disorder disease portfolio.

BRIEF-Agios And Royalty Pharma Announce $255 Mln Purchase Agreement For IDHIFA Royalty

* AGIOS AND ROYALTY PHARMA ANNOUNCE $255 MILLION PURCHASE AGREEMENT FOR IDHIFA® ROYALTY

BRIEF-Thermo Fisher To Co-Develop A Global Companion Diagnostic For Low-Grade Glioma With Agios Pharmaceuticals

* THERMO FISHER SCIENTIFIC - TO CO-DEVELOP A GLOBAL COMPANION DIAGNOSTIC FOR LOW-GRADE GLIOMA WITH AGIOS PHARMACEUTICALS

BRIEF-Agios Announces FDA Orphan Drug Designation Granted To Mitapivat For Treatment Of Thalassemia

* AGIOS ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO MITAPIVAT FOR TREATMENT OF THALASSEMIA Source text for Eikon: Further company coverage:

BRIEF-Agios Pharma Says Vorasidenib Demonstrated Prolonged Disease Control, Encouraging Preliminary Activity

* AGIOS PHARMA -VORASIDENIB DEMONSTRATED PROLONGED DISEASE CONTROL, ENCOURAGING PRELIMINARY ACTIVITY WITH MEDIAN PROGRESSION-FREE SURVIVAL OF 31.4 MONTHS

BRIEF-Agios Reports First Quarter 2020 Financial Results

* AGIOS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE ON BUSINESS OPERATIONS AND COVID-19 RESPONSE

BRIEF-Agios Receives Positive Opinion On Orphan Drug Designation From European Medicines Agency For Mitapivat In Pyruvate Kinase Deficiency

* AGIOS RECEIVES POSITIVE OPINION ON ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR MITAPIVAT IN PYRUVATE KINASE DEFICIENCY Source text for Eikon: Further company coverage:

BRIEF-Agios Provides Update On 2016 Collaboration Agreement With Celgene

* AGIOS PROVIDES UPDATE ON 2016 COLLABORATION AGREEMENT WITH CELGENE, A WHOLLY OWNED SUBSIDIARY OF BRISTOL MYERS SQUIBB

BRIEF-Agios Pharmaceuticals Expects To Initiate AG-946 Phase 1 Study In Mid-Year 2020

* AGIOS PHARMACEUTICALS INC - EXPECTS TO INITIATE AG-946 PHASE 1 STUDY IN MID-YEAR 2020 Source text for Eikon: Further company coverage:

BRIEF-Agios Reports Q4 Loss Per Share Of $1.60

* AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up